Takeda Pharmaceutical (NYSE:TAK) Issues FY 2024 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 3.330-3.330 for the period. The company issued revenue guidance of $30.1 billion-$30.1 billion.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $13.41 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. Takeda Pharmaceutical has a 1-year low of $12.57 and a 1-year high of $15.08. The firm has a market capitalization of $42.65 billion, a P/E ratio of 23.11, a P/E/G ratio of 0.25 and a beta of 0.51. The business’s 50-day simple moving average is $13.31 and its 200-day simple moving average is $13.88.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 6.49% and a return on equity of 10.00%. Equities analysts predict that Takeda Pharmaceutical will post 1.55 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.